The airline of this tiny Pacific nation has introduced a long-lasting treatment to kill surface Coronavirus – and it’s now available in India.

The Republic of Nauru is a tiny island nation in the South-West Pacific, with a total area of just 21 square kilometres, and a population nearing 11,000.

The entire country is half the size of New Delhi, and the republic’s population could be carried on three rush-hour trains in the Indian capital.

With such small scale, and in the midst of this global pandemic, Nauru is highly vulnerable to the COVID-19 virus, and has applied stringent biosecurity protocols to help protect public and economic health from external infection.

As the national flag carrier, Nauru Airlines is a key enabler of economic prosperity, with five Boeing 737 jets providing passenger and freight links to destinations around the South Pacific. 

The airline also plays a critical role in humanitarian activities, most recently delivering emergency supplies to cyclone-hit Fiji. 

To help protect its aircraft, their occupants, and the nation, against COVID-19, Nauru Airlines has introduced the A333 ‘antimicrobial shield’, a treatment developed by Sydney-based biotechnology company Hygiene Labs.

The treatment has been independently verified to inactivate surface-borne viral contaminants including COVID-19 and Norovirus for up to 28 days, and has secured Australian regulatory listing attesting to this length of effectiveness.

It is also one of few, if any, such treatments globally to offer such protection – and is now available in India to protect all forms of public and private transport, passenger terminals, retail centres, hotels, offices, and facilities. 

For more information in India, visit or call Hygiene Labs India Represented by Good Fellas Enterprise LLP on +91-982 558 8233.